Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Laboratorios Silanes S A De C V currently manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 3 distinct art units, indicating that the company's pharmaceutical innovations are being evaluated by several different specialized technical groups. The involvement of 3 distinct examiners across these 4 pending office actions suggests variety in the prosecution experience for the company.
TCHERKASSKAYA, OLGA V is the busiest examiner for this entity, currently handling 2 pending office actions. This concentration represents 2 of the 4 pending office actions, making her examination style a factor in the overall success of the portfolio. The remaining actions are handled by the other examiners, requiring the company to adapt to different individual preferences within the Biotechnology & Pharmaceuticals sector. Practitioners should monitor the 3 distinct art units closely to ensure that arguments remain consistent even when presented to different examiners with potentially different perspectives.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TCHERKASSKAYA, OLGA V | 2 | 55.5% | +46.4% |
| ROSENTHAL, ANDREW S | 1 | 51.9% | +39.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18028625 | PHARMACEUTICAL COMBINATIONS OF STATINS AND FIBRATES FOR THE TREATMENT AND PREVENTION OF HYPERLIPIDEMIAS AND CARDIOVASCULAR DISEASE | TCHERKASSKAYA, OLGA V | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18255244 | STABLE COATED SOLID PHARMACEUTICAL COMPOSITION OF AN OPIOID ANALGESIC AND AN ANTI-EPILEPTIC FOR PAIN | TCHERKASSKAYA, OLGA V | 21d |
| 18028625 | PHARMACEUTICAL COMBINATIONS OF STATINS AND FIBRATES FOR THE TREATMENT AND PREVENTION OF HYPERLIPIDEMIAS AND CARDIOVASCULAR DISEASE | TCHERKASSKAYA, OLGA V | 34d |
| 18906605 | CELECOXIB - ACETAMINOPHEN COMBINATION OF IMPROVED STABILITY AND PREPARATION PROCEDURE | ROSENTHAL, ANDREW S | — |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18906605 | CELECOXIB - ACETAMINOPHEN COMBINATION OF IMPROVED STABILITY AND PREPARATION PROCEDURE | ROSENTHAL, ANDREW S | 1613 | §103Other | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18255244 | STABLE COATED SOLID PHARMACEUTICAL COMPOSITION OF AN OPIOID ANALGESIC AND AN ANTI-EPILEPTIC FOR PAIN | TCHERKASSKAYA, OLGA V | 1615 | §103 | Non-Final OA | 21d | Pending | May 31, 2023 |
| 18028625 | PHARMACEUTICAL COMBINATIONS OF STATINS AND FIBRATES FOR THE TREATMENT AND PREVENTION OF HYPERLIPIDEMIAS AND CARDIOVASCULAR DISEASE | TCHERKASSKAYA, OLGA V | 1615 | §103§112 | Non-Final OA | 34d | Pending | Mar 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLaboratorios Silanes S A De C V has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Olga V Tcherkasskaya has the most, with 2 of Laboratorios Silanes S A De C V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
